A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

• DOI: 10.1038/s41467-022-31328-x
• Publication Date: 2022-06-24T12:03:41Z
• Authors: Hongwei Jiang; Shuguang Pang; Yawei Zhang; Ting Yu; Meng Liu; Huan Deng; Li Li; Liqi Feng; Baili Song; Han Han-Zhang; Qingyang Ma; Lei Qian; Wenying Yang
• Keywords: Dulaglutide; Tolerability

Abstract The success of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes (T2D) and obesity has sparked considerable efforts develop next-generation co-agonists that are more effective. We conducted a randomised, placebo-controlled phase 1b study (ClinicalTrials.gov: NCT04466904) evaluate the safety efficacy IBI362 (LY3305677), GLP-1 glucagon dual agonist, in Chinese patients with T2D. A total 43 T2D were enrolled three cohorts nine centres China randomised each cohort receive once-weekly (3.0 mg, 4.5 mg or 6.0 mg), placebo open-label dulaglutide (1.5 mg) subcutaneously for 12 weeks. Forty-two received treatment included analysis, eight receiving IBI362, four two cohort. patients, investigators site personnel involved treating assessing masked allocation. Primary outcomes tolerability IBI362. Secondary change glycated haemoglobin 1c (HbA ), fasting plasma glucose (FPG) post-mixed-meal tolerance test (post-MTT) levels. was well tolerated. Most commonly-reported treatment-emergent adverse events diarrhoea (29.2% 33.3% dulaglutide, 0% placebo), decreased appetite (25.0% 16.7% placebo) nausea (16.7% 8.3% placebo). HbA , FPG post-MTT levels reduced from baseline week all cohorts. showed favourable profile clinically meaningful reductions blood